Get the Stockscreener App
74.92
0.25%
-0.19
After Hours:
74.92
Edwards Lifesciences Corp stock is traded at $74.92, with a volume of 2.34M.
It is down -0.25% in the last 24 hours and up +8.02% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$75.11
Open:
$74.41
24h Volume:
2.34M
Relative Volume:
0.54
Market Cap:
$44.68B
Revenue:
$5.54B
Net Income/Loss:
$4.18B
P/E Ratio:
10.70
EPS:
7
Net Cash Flow:
$259.90M
1W Performance:
-1.78%
1M Performance:
+8.02%
6M Performance:
+13.95%
1Y Performance:
-11.95%
1-Day Range:
$74.25
$75.36
1-Week Range:
$74.15
$77.12
52-Week Range:
$58.93
$95.25
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
74.92 | 44.68B | 5.54B | 4.18B | 259.90M | 7.00 |
|
ABT
Abbott Laboratories
|
133.06 | 227.05B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.12 | 152.00B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
377.52 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.32 | 108.50B | 33.20B | 4.26B | 5.47B | 3.29 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan
Edwards Lifesciences Gets FDA Approval for TAVR in Asymptomatic Aortic Stenosis - marketscreener.com
Edwards wins FDA nod for TAVR in aortic stenosis without symptoms - MassDevice
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis - BioSpace
FDA approves Edwards Lifesciences’ TAVR therapy By Investing.com - Investing.com India
FDA Approves First-Ever TAVR Treatment for Asymptomatic Aortic Stenosis Patients - Stock Titan
Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite? - Insider Monkey
Commit To Purchase Edwards Lifesciences At $60, Earn 6.8% Using Options - Nasdaq
Edwards Lifesciences Corporation (NYSE:EW) Q1 2025 Earnings Call Transcript - Insider Monkey
Edwards Lifesciences Reports Robust Q1 2025 Growth - TipRanks
Edwards Lifesciences (EW) Price Target Raised by Canaccord Analy - GuruFocus
Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook BrightensEdwards Lifesciences (NYSE:EW) - Benzinga
Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings - Yahoo Finance
Edwards Lifesciences Corp (EW) Shares Up 7.25% on Apr 24 - GuruFocus
This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Stifel maintains Edwards Lifesciences stock with $90 target - Investing.com
Bernstein Adjusts Price Target on Edwards Lifesciences to $80 From $78 - marketscreener.com
Edwards Lifesciences Raises 2025 Sales Forecast Amid Currency Boost - Finimize
Edwards Lifesciences (EW) Price Target Raised by Baird Amid Mixed Q1 Results | EW Stock News - GuruFocus
EW Q1 Earnings & Revenues Beat, Stock Climbs, '25 Sales View Raised - Yahoo Finance
Edwards Lifesciences (EW) Receives Upgrade from Piper Sandler, T - GuruFocus
Edwards Lifesciences (EW) Receives Upgrade from Piper Sandler, Target Raised | EW Stock News - GuruFocus
Piper Sandler raises Edwards Lifesciences stock to Overweight - Investing.com
Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ... - Yahoo Finance
Earnings call transcript: Edwards Lifesciences Q1 2025 beats EPS forecast - Investing.com
Earnings call transcript: Edwards Lifesciences Q1 2025 beats EPS forecast By Investing.com - Investing.com UK
Edwards Lifesciences Corp (EW) Q1 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Milestones - GuruFocus
Edwards Lifesciences (EW) Reports Strong Q1 2025 Growth on Cardi - GuruFocus
Edwards Lifesciences Reports Strong Q1 Growth - TipRanks
Edwards posts Street-beating Q1 results, ups 2025 sales guidance - MassDevice
Edwards Lifesciences Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Edwards Lifesciences (EW) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Edwards Lifesciences Corp Q1 2025 Earnings: EPS of $0.62 Beats E - GuruFocus
Edwards Lifesciences raises 2025 sales forecast after robust quarter - marketscreener.com
Edwards Lifesciences Q1 Adjusted Earnings, Sales Rise; Provides Q2 Guidance - marketscreener.com
Innovative Strategy Boosts Edwards Lifesciences (EW) Q1 Revenue Above Expectations | EW Stock News - GuruFocus
Edwards Lifesciences Delivers In-Line Sales, Narrow Profit Beat - MSN
Edwards Lifesciences Reports First Quarter Results - TradingView
Edwards Lifesciences Corp. Reveals Climb In Q1 Profit - Nasdaq
Earnings Flash (EW) Edwards Lifesciences Reports Q1 Adjusted EPS $0.64, vs. FactSet Est of $0.60 - marketscreener.com
Edwards Lifesciences Crushes Q1 Expectations: TMTT Sales Surge 58%, New SAPIEN M3 Approval Fuels Growth - Stock Titan
EDWARDS LIFESCIENCES Earnings Preview: Recent $EW Insider Trading, Hedge Fund Activity, and More - Nasdaq
Eight-Year Data Confirm Long-Term Durability of Edwards’ RESILIA Tissue - BioSpace
Lobbying Update: $350,000 of EDWARDS LIFESCIENCES LLC lobbying was just disclosed - Nasdaq
Edwards touts 8-year data for Resilia valve tissue - MassDevice
Unlocking Q1 Potential of Edwards Lifesciences (EW): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Edwards Lifesciences (EW) Shares Surge on Promising Aortic Valve Study Results | EW Stock News - GuruFocus
Breakthrough: Edwards Heart Valves Achieve 99.3% Success Rate in Landmark 8-Year Study - Stock Titan
Is Edwards Lifesciences Gaining or Losing Market Support?Edwards Lifesciences (NYSE:EW) - Benzinga
Solid TMTT Growth to Drive Edwards Lifesciences' Q1 Earnings - MSN
Edwards Lifesciences to Host Earnings Conference Call on April 23, 2025 - marketscreener.com
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.57%
3.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):